Amgen (AMGN) PT Raised to $195 at Barclays
Tweet
Share
E-mail
Get Alerts AMGN Hot Sheet
Price: $374.15 +3.55%
Rating Summary:
20 Buy, 18 Hold, 5 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 0 | Down: 0 | New: 2
Rating Summary:
20 Buy, 18 Hold, 5 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 0 | Down: 0 | New: 2
Join SI Premium – FREE
Barclays raised its price target on Amgen (NASDAQ: AMGN) to $195.00 (from $180.00) while maintaining a Equalweight rating following the company's 2Q earnings report.
Amgen’s portfolio looks poised to deliver flat growth in 2018e, which, in Barclays view, will likely keep shares in a holding pattern in the near term. For the year, Barclays forecasts top-line decline of -1.6% and -3.1% in 2019. On the bottom line, the company is expected to accelerate growth through its low tax rate and additional share repurchase programs.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Freedom Broker Starts Unity Bancorp (UNTY) at Hold
- Trump said he was unaware of his earnings from crypto
- FactSet Research Systems (FDS) PT Raised to $253 at Jefferies
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst PT ChangeRelated Entities
Barclays, EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
